Background: Oral contraceptives (OC) containing different types of progestogens induce
different sensitivities to activated protein C (APC) measured with the thrombin generation …

Oral contraceptive (OC) use is associated with an increased risk of venous
thromboembolism. Previous data reported higher thrombotic risk in women using third …

Use of combined oral contraceptives is associated with a three-to sixfold increased risk of
venous thrombosis. Hormonal contraceptives induce acquired resistance to activated …

BACKGROUND: Epidemiological studies have shown that both the estrogen dose and
progestogen type of oral contraceptives contribute to the increased risk of thrombosis in oral …

Resistance to activated protein C (APC resistance) is an important and common risk factor
for deep vein thrombosis. The majority of patients with APC resistance carry a mutation on …

Exogenously administered estrogens and progestogens as during combined oral
contraceptive use increase the risk of venous thrombosis. The thrombin generation-based …

Activated protein C (APC) resistance, determined with a thrombin‐generation‐based APC
resistance test, may explain risk differences of venous thrombosis in users of second‐and …

Resistance to activated protein C (APC) is often associated with a mutation in factor V (factor
VLeiden). Individuals without factor VLeiden who exhibit a response in functional APC …

Recent studies suggest that low‐dose oral contraceptives may cause acquired resistance to
activated protein C (APC). The aims of this study were to determine whether hormone …

Background We have reported previously that, compared with use of second-generation oral
contraceptives, the use of third-generation oral contraceptives is associated with increased …